“A Multicentric, Open-Label, Single Arm Phase II Study To Evaluate The Efficacy And Safety Of The Combination Of PEmbrolizumab And Lenvatinib In Pre-Treated Thymic CArcinoma PaTIents. PECATI”.
This research study, called PECATI, is looking at a new way to treat a rare cancer called thymic carcinoma, especially a subtype called B3-thymoma, when it has spread. The study is for patients who have already had other treatments. We are testing a combination of two medicines, Keytruda (pembrolizumab) and Lenvatinib. The main goal is to see if this new treatment can stop the cancer from growing or spreading for at least five months. Doctors are also carefully checking how safe the treatment is and what side effects people might have. This is a "Phase II" study, which means it helps us understand if the treatment is promising enough for larger studies in the future. It's a way to find better treatment options for this specific cancer.
At a glance
What is this study about?
This study, known as PECATI, is focused on finding better treatments for a rare type of cancer called thymic carcinoma, or a specific variant called B3-thymoma, particularly when the cancer has spread in the body and other treatments haven't worked or stopped working. Doctors are exploring a combination of two established anti-cancer medicines, Keytruda (which is also known by its active ingredient, pembrolizumab) and Lenvatinib.
The main aim of this study is to see how well this new combination treatment works. Specifically, they want to know if it can stop the cancer from growing or spreading for at least five months in people with this condition. They will also be closely monitoring any side effects to understand how safe and well-tolerated the treatment is. This research is important because thymic carcinoma is uncommon, and finding effective new treatments can make a big difference for patients.
This is a Phase II study, which means it's an important step in testing new treatments. If the results are promising, it can lead to larger studies involving more people, bringing us closer to new approved treatments. It’s about gathering information to help improve care for patients like you in the future.
Key takeaways
- This study tests two medicines, Keytruda and Lenvatinib, for advanced thymic carcinoma.
- It aims to see if the treatment stops cancer growth for at least 5 months.
- Patients must be 18 or older and have had previous cancer treatments.
- It's a Phase II study, seeking safer and more effective treatment options.
- You'll have regular medical checks and scans if you participate.
Who may be eligible?
To be considered for this study, you would need to be an adult, 18 years of age or older. There is no upper age limit, meaning older adults can also take part. The study is open to both men and women.
Crucially, you must have a diagnosis of metastatic thymic carcinoma or B3-thymoma. This means your cancer has spread beyond its original location. You also need to have already received other treatments for your cancer before being considered for this study.
This study is for people whose cancer has progressed or returned after previous treatments. The research team will carefully check your full medical history and conduct tests to make sure the study treatment is suitable and safe for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Have you been diagnosed with metastatic thymic carcinoma or B3-thymoma?
- Have you already received other treatments for your cancer?
- Are you able to attend regular clinic visits and tests?
What does participation involve?
If you decide to take part in this study, you will receive the combination of two medicines: Keytruda, given as an infusion into a vein, and Lenvatinib, taken as a pill. The study treatment will continue as long as it benefits you and you tolerate it well. You will have regular visits to the clinic for medical check-ups, blood tests, and scans (like CT or MRI scans) to monitor your health and how the treatment is working. These tests will help the doctors track the cancer and any side effects. The total duration you participate will depend on how you respond to the treatment, but the main goal is to assess what happens in the first five months.
Potential risks and benefits
Locations (3)
- —UnverifiedSpain
- —UnverifiedFrance
- —UnverifiedItaly
Common questions
What is 'thymic carcinoma'?
Thymic carcinoma is a rare type of cancer that starts in a gland behind your breastbone called the thymus.
What does 'metastatic' mean?
Metastatic means that the cancer has spread from where it first started to other parts of your body.
What are Keytruda and Lenvatinib?
They are different types of medicines used to treat cancer. Keytruda helps your body's immune system fight the cancer, and Lenvatinib blocks signals that help cancer cells grow.
What does 'progression free survival' mean?
It means the length of time a person lives with the disease without it getting worse or spreading.
Can I take part if I've had other treatments?
Yes, this study is specifically for people who have already received other treatments for their thymic carcinoma.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.